Skip to main content

Table 2 Multivariable adjusted risks of CVD and hard CVD based on different glucose intolerance categories. (n = 408)

From: Long term prognostic implication of newly detected abnormal glucose tolerance among patients with stable cardiovascular disease: a population-based cohort study

 

CVD HR (95%CI)

Hard CVD HR (95%CI)

E/N

Model 1

Model 2

E/N

Model 1

Model 2

FPG-WHO (mmol/L)

  < 6.1

169/327

1.00

1.00

66/327

1.00

1.00

 6.1–6.9

21/44

0.92 (0.58–1.45)

0.87 (0.55–1.39)

10/44

1.13 (0.58–2.21)

0.97 (0.49–1.93)

  ≥ 7

30/37

2.02 (1.36–3.00)

2.07 (1.39–3.12)

13/37

1.95 (1.07–3.53)

2.02 (1.07–3.80)

FPG-ADA (mmol/L)

  < 5.6

129/253

1.00

1.00

45/253

1.00

1.00

 5.6–6.9

61/118

1.07 (0.79–1.46)

1.05 (0.77–1.44)

31/118

1.62 (1.03–2.57)

1.52 (0.95–2.45)

  ≥ 7

30/37

2.09 (1.40–3.12)

2.15 (1.41–3.27)

13/37

2.28 (1.23–4.22)

2.41 (1.25–4.67)

2 h-PCPG (mmol/L)

  < 7.8

123/240

1.00

1.00

50/240

1.00

1.00

 7.8–11.0

54/105

1.01 (0.73–1.39)

0.97 (0.70–1.36)

20/105

0.93 (0.55–1.56)

0.90 (0.53–1.55)

  ≥ 11

43/63

1.48 (1.04–2.10)

1.46 (1.02–2.11)

19/63

1.59 (0.93–2.70)

1.54 (0.88–2.70)

  1. Model 1: age and sex
  2. Model 2: model 1+ body mass index, current smoking, family history of premature CVD, hypertension, hypercholesterolemia, low HDL-C, heart rate, use of aspirin, use of beta blockers and low physical activity.
  3. E event in the target group, N total sample size in the target group, CVD cardiovascular disease, CHD coronary heart disease, HR hazard ratio, CI confidence interval, FPG fasting plasma glucose, 2h-PCPG 2h post challenge plasma glucose, WHO World Health Organization, ADA American Diabetes Association